Patent SG-11201808909W-A (SG)
Title: Ex vivo bite-activated t cells
Inventor: BALLESTEROS NOBELL JUAN ANTONIO
IPC: A61K39/00
Filed: 2017-04-12
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111 010111110111010111 ME1001111101111111011110111111 International Bureau ... ..... ..Yi j (10) International Publication Number ..... .....!;,,, (43) International Publication Date WO 2017/178572 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle A61K 39/00 (2006.01) Santiago Grisolia, Suite 205, 28760 Madrid (ES). (21) International Application Number: (74) Agent: ILLESCAS TABOADA, Manuel; C/ Principe de PCT/EP2017/058891 Vergara, 197, Oficina 1° A, 28002 Madrid (ES). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 12 April 2017 (12.04.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (30) Priority Data: 62/321,964 13 April 2016 (13.04.2016) US KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (71) Applicant: V1VIA BIOTECH, S.L [ES/ES]; Parque Cien- tifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: BALLESTEROS NOBELL, Juan Antonio; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). BENNET, Teresa Ann; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). HERNANDEZ CAMPO, Pilar; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). GOMEZ GONZALEZ, Cristina; VWIA BIOTECH, S.L, Parque Cientifico Madrid (PCM), 1, Calle Santiago Griso- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — _ = = lia, Suite 205, 28760 Madrid (ES). GORROCHATEGUI Published: GUILLEN, Julian; VWIA BIOTECH, S.L, Parque Cien- — tifico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, — with international search report (Art. 21(3)) = = 28760 Madrid (ES). MARTINEZ LOPEZ, Joaquin; — before the expiration of the time limit for amending the Calle Melilla num. 6 6°B, 28005 Madrid (ES). ROBLES claims and to be republished in the event of receipt of — MATEOS, Alicia; VWIA BIOTECH, S.L, Parque Cienti- fico Madrid (PCM), 1, Calle Santiago Grisolia, Suite 205, 28760 Madrid (ES). PRIMO RAMOS, Daniel; VWIA amendments (Rule 48.2(h)) = = = = = = = = 1-1 ei IN kin cc IN 1-1 (54) Title: EX VIVO BITE-ACTIVATED T CELLS I r ----- (57) : Generation and identification of highly effective immune effector cell in terms of target cell-killing activity can be en- 1-1 hanced by optimizing the proximity between a target cell and the immune effector cell. The cancer-killing T cells described herein ei can provide highly effective therapies for diverse cancer types, e.g., solid cancers, hematological cancers, and metastatic forms there - tom.) of. Provided herein are ex-vivo methods of generating cancer-killing T cells, compositions comprising such immune cells; methods ,7 1 1 . 9 of using the cells, methods of selecting optimal agents for enhancing the target cell killing activity, methods of selecting an optim- ized immune cell and methods of using this approach to evaluate patient responsiveness to other cancer therapies.